Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
5(100.0%)
5Total
Early Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07277504Early Phase 1Not Yet Recruiting

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Role: collaborator

NCT07274059Early Phase 1Recruiting

Allogeneic UCB-derived CAR-T for SLE

Role: lead

NCT07266337Early Phase 1Not Yet Recruiting

CD19/BCMA CAR-T for SLE

Role: lead

NCT07266311Early Phase 1Not Yet Recruiting

CAR-T for Claudin18.2 Positive Solid Tumors

Role: lead

NCT07256353Early Phase 1Not Yet Recruiting

Allogeneic UCB-derived CAR-T for B-ALL

Role: collaborator

All 5 trials loaded